PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: David J. Cohen

REGISTER for free or LOG IN to view this content

Become a GOLD or PLATINUM member to access PowerPoint files, presentation audio, and video

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

We Recommend